Plasminogen activator inhibitor-1 in cancer: Rationale and insight for future therapeutic testing

Cancer Research

Volumn 75, Issue 15, 2015, Pages 2969-2974

  Placencio, Veronica R ^a,b   DeClerck, Yves A ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; 2 ACYLAMINO 3 THIOPHENECARBOXYLIC ACID DERIVATIVE; ALEPLASININ; ANTHRANILIC ACID DERIVATIVE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BENZOTHIOPHENE; CARBOXYLIC ACID DERIVATIVE; CDE 066; CDE 096; DIAPLASININ; PIPERAZINEDIONE; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYPHENOL DERIVATIVE; SK 116; SK 216; TIPLASININ; TISSUE PLASMINOGEN ACTIVATOR; TM 5001; TM 5007; TM 5275; TM 5441; UNCLASSIFIED DRUG; XR 1853; XR 334; XR 5082; XR 5118; SERPINE1 PROTEIN, HUMAN;

ANGIOGENESIS; ARTERY THROMBOSIS; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; CARCINOGENESIS; CELL SURVIVAL; HUMAN; LUNG CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR CELL; UTERINE CERVIX CANCER; ANIMAL; APOPTOSIS; DISEASE MODEL; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84941674463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0876     Document Type: Article

References (58)

1. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008;36:184-94.
2. Schroeck F, Arroyo de Prada N, Sperl S, Schmitt M, Viktor M. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol Chem 2002;383: 1143-9.
3. Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013;39: 382-91.
4. Wind T, Hansen M, Jensen JK, Andreasen PA. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem 2002; 383:21-36.
5. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
6. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100.
7. Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010;4:315-24.
8. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for anti-angiogenic strategies. J Cell Biol 2001;152:777-84.
9. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Durden DL, et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001;61: 5587-94.
10. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
11. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer cell 2008;14:324-34.
12. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through anantiapoptotic function. J Natl Cancer Inst 2012;104:1470-84.
13. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014;156:1002-16.
14. Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006;281:22527-36.
15. Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost 2008;100:1037-40.
16. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000;60:5839-47.
17. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor1prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
18. Lademann U, Romer MU, Jensen PB, Hofland KF, Larsen L, Christensen IJ, et al. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur J Cancer 2005;41: 1095-100.
19. Romer MU, Kirkebjerg Due A, Knud Larsen J, Hofland KF, Christensen IJ, Buhl-Jensen P, et al. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb Haemost 2005;94:859-66.
20. Romer MU, Larsen L, Offenberg H, Brunner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 2008;10:1083-91.
21. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996;87:4718-22.
22. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-8.
23. Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005;7:57-66.
24. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003;22:4389-97.
25. Fen Li C, Kandel C, Baliko F, Nadesan P, Brunner N, Alman BA. Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). Oncogene 2005;24:1615-24.
26. Maillard CM, Bouquet C, Petitjean MM, Mestdagt M, Frau E, Jost M, et al. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis 2008; 29:2236-42.
27. Masset A, Maillard C, Sounni NE, Jacobs N, Bruyere F, Delvenne P, et al. Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int J Cancer 2011;128:283-93.
28. Biliran H Jr, Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 2001;61:8676-82.
29. Espana F, Estelles A, Fernandez PJ, Gilabert J, Sanchez-Cuenca J, Griffin JH. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thromb Haemost 1993;70:989-94.
30. Montemurro P, Barbuti G, Conese M, Gabriele S, Petio M, Colucci M, et al. Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis. Br J Haematol 1999;107:294-9.
31. Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, et al. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985;260:7029-34.
32. Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat 2013;23:801-15.
33. Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996;75: 808-15.
34. Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, et al. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 1997;96:916-21.
35. Liang A, Wu F, Tran K, Jones SW, Deng G, Ye B, et al. Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res 2005;115:341-50.
36. Rupin A, Gaertner R, Mennecier P, Richard I, Benoist A, De Nanteuil G, et al. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res 2008;122:265-70.
37. Miyazaki H, Ogiku T, Sai H, Ohmizu H, Murakami J, Ohtani A. Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg Med Chem Lett 2008;18: 6419-22.
38. Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, et al. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004;47:3491-4.
39. Hennan JK, Morgan GA, Swillo RE, Antrilli TM, Mugford C, Vlasuk GP, et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008;6:1558-64.
40. Lucking AJ, Visvanathan A, Philippou H, Fraser S, Grant PJ, Connolly TM, et al. Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost 2010;8:1333-9.
41. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008;105:8754-9.
42. Barker R, Kehoe PG, Love S. Activators and inhibitors of the plasminogen system in Alzheimer's disease. J Cell Mol Med 2012;16:865-76.
43. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008;28:672-7.
44. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, et al. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab 2010;30:904-12.
45. Yamaoka N, Kawano Y, Izuhara Y, Miyata T, Meguro K. Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. Chem Pharm Bull 2010; 58:615-9.
46. Gorlatova NV, Cale JM, Elokdah H, Li D, Fan K, Warnock M, et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 2007;282:9288-96.
47. Rouch A, Vanucci-Bacque C, Bedos-Belval F, Baltas M. Small molecules inhibitors of plasminogen activator inhibitor-1 - An overview. Eur J Med Chem 2015;92:619-36.
48. Cale JM, Li SH, Warnock M, Su EJ, North PR, Sanders KL, et al. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 2010;285:7892-902.
49. Li SH, Reinke AA, Sanders KL, Emal CD, Whisstock JC, Stuckey JA, et al. Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1. Proc Natl Acad Sci U S A 2013;110:E4941-9.
50. Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008;29:824-9.
51. Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, et al. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther 2013;12:2378-88.
52. Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther 2013;12: 2697-708.
53. Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, et al. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther 2015:16:253-60.
54. Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity. PLoS ONE 2015 (manuscript submitted).
55. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988;263: 15454-61.
56. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997;90:204-8.
57. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999;7:111-8.
58. Stout TJ, Graham H, Buckley DI, Matthews DJ. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 2000;39:8460-9.